|
| Welcome COW Editorial Board CME Accreditation Grant Support Mailing List Presentation Archive Return to Main Site |
|
Disclosure of Financial Interests In the interest of maintaining the independence of its continuing medical education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International Antiviral Society–USA requires all persons with control of content (eg; authors, reviewers, Editorial Board members, and the staff of the Cases on the Web program) to disclose any financial interests that they (or their spouses or partners) have with commercial companies within the past 12 months.
Cases on the Web Editorial Board The members of the Cases on the Web (COW) Editorial Board are volunteers and are not compensated for their role in overseeing the program. Listed below are the COW Editorial Board members and their financial interests with commercial companies within the past 12 months from the date of disclosure. Michael S. Saag, MD — Editor-in-Chief Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 10/04/11) Marshall J. Glesby, MD, PhD — Coeditor Dr Glesby has received grants and research support awarded to Weill Cornell Medical College from Pfizer Inc, and he served as a consultant to Pfizer Inc. and SIGA Technologies. (Updated 01/28/12) Judith A. Aberg, MD Dr Aberg has been a scientific advisor to Merck & Co, Inc, Tibotec Therapeutics and ViiV Healthcare. She will receive clinical research support awarded to New York University School of Medicine from Kowa Research Institute in 2012. She participates in multicenter clinical trials from Gilead Sciences, Inc, Glaxo-Smith-Kline, Kowa Research Institute, Pfizer Inc, and Tibotec Therapeutics. (Updated 01/27/12) Roger J. Bedimo, MD, MS Dr Bedimo has been a scientific advisor to Gilead Sciences, ViiV Healthcare, and EMD Serono, Inc. He has received grants and research support awarded to University of Texas Southwestern Medical Center from Merck & Co, Inc and Tibotec Therapeutics. (Updated 01/30/12) Meg D. Newman, MD Dr Newman has no relevant financial affiliations to disclose. (Updated 1/28/12) Paul E. Sax, MD Dr Sax has received grants and research support awarded to Harvard Medical School from Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Tibotec Therapeutics. He has served as a consultant to Abbott Laboratories, Aileron Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Tibotec Therapeutics. (Updated 01/30/12) Steven C. Johnson, MD Dr Johnson has served as a consultant to Gilead Sciences, Janssen Therapeutics, and ViiV Healthcare. (Updated 1/28/12) Harry W. Lampiris, MD Dr Lampiris has no relevant financial affiliations to disclose. (Updated 01/30/12) David L. Wyles, MD Dr Wyles has received grants awarded to the University of California San Diego from Gilead Sciences, Inc, Pharmasset, Inc, and Vertex Pharmaceuticals. He also served as a consultant to Bristol-Myers Squibb and Merck & Co, Inc. He has developed educational presentations for QuantiaMD. (Updated 01/30/12) J. Martin Rodriguez, MD, FACP Dr Rodriguez has received grants awarded to the University of Alabama at Birmingham from Merck & Co., Inc. (Updated 01/30/12) David McCollum, MD – Fellow Editor Dr McCollum has no relevant financial affiliations to disclose. (Updated 01/28/12) Staff of the Cases on the Web Donna M. Jacobsen — Executive Director/President Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 1/27/12) Donna L. Scism — Cases on the Web Program Coordinator Ms Scism has no relevant financial affiliations to disclose. (Updated 1/27/12) IAS–USA Board of Directors The nonstaff members of the IAS–USA Board of Directors participate in a volunteer capacity. They are not compensated for their roles in governing/overseeing the IAS–USA. Listed below are the IAS–USA Board of Directors and their financial interests with commercial companies within the last 12 months from the date of disclosure. Constance A. Benson, MD Dr Benson has no relevant financial affiliations to disclose. (Updated 10/03/11) Judith S. Currier, MD Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. (Updated 10/03/11) Carlos del Rio, MD Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp (now Merck & Co, Inc), and Sanofi Pasteur and has served as a consultant to Gilead Sciences, Inc. (Updated 09/27/11) Joel E. Gallant, MD, MPH Dr Gallant has served as a consultant to or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Janssen Therapeutics, RAPID Pharmaceuticals, and Sangamo Bioscience. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences, Inc. (Updated 09/28/11) Roy M. Gulick, MD, MPH Dr Gulick has received grants and research support from Merck & Co, Inc, Pfizer Inc, Tibotec Therapeutics, ViiV Healthcare, and Vircostatics. He has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, ViiV Healthcare, and ViroStatics. He has received travel, accommodations, or meeting expenses related or unrelated to activities listed from Bristol-Myers Squibb, Gilead Sciences, Merck & Co, Inc, Tibotec Therapeutics, ViiV Healthcare, and Virostatics. (Updated 09/07/11) Douglas D. Richman, MD Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, Chemerix, Gen-Probe Inc, Gilead Sciences, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc. He has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of Chemerix. (Updated 09/28/11) Michael S. Saag, MD — Editor-in-Chief Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 10/04/11) Robert T. Schooley, MD Dr Schooley has served as a consultant to Gilead Sciences, Inc, Inhibitex, Inc, Johnson & Johnson Services, Inc, Laboratory Corporation of America, Merck & Co, Inc, Santaris Pharma, and Tobira Therapeutics. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 09/28/11) Paul A. Volberding, MD Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb, and Gilead Sciences, Inc. He has served on data and safety monitoring boards for Gilead Sciences, Inc. (Updated 09/28/11) If you have any questions about the COW Editoria Board or their financial (COI) disclosures,please contact the International Antiviral Society–USA:
|
|
||
Back to Top |
|||